Histologic Response Up With Benralizumab for Eosinophilic Esophagitis
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 26, 2024 -- Benralizumab yields a greater histologic response than placebo for patients with eosinophilic esophagitis, but does not affect dysphagia symptoms, according to a study published in the June 27 issue of the New England Journal of Medicine.
Marc E. Rothenberg, M.D., Ph.D., from the Leiden University Medical Center in the Netherlands, and colleagues conducted a phase 3 randomized trial involving patients aged 12 to 65 years with symptomatic and histologically active eosinophilic esophagitis. Participants were randomly assigned to receive benralizumab (30 mg) or placebo every four weeks (104 and 107 patients, respectively).
The researchers found that more patients had a histologic response to benralizumab than placebo at 24 weeks (87.4 versus 6.5 percent). However, no significant between-group difference was seen for the change from baseline in the Dysphagia Symptom Questionnaire score. Furthermore, no substantial between-group difference was seen in the change from baseline in the Eosinophilic Esophagitis Endoscopic Reference Score. Overall, 64.1 and 61.7 percent of patients in the benralizumab and placebo groups, respectively, reported adverse events.
"Benralizumab resulted in a higher incidence of histologic response than placebo but did not result in a greater reduction in dysphagia symptoms," the authors write. "This trial calls into question the clinical relevance of monitoring eosinophilic esophagitis for treatment effect solely on the basis of the degree of eosinophilic inflammation."
Several authors disclosed ties to AstraZeneca, which manufactures benralizumab and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Dupilumab Ups Histologic Response for Pediatric Eosinophilic Esophagitis
THURSDAY, June 27, 2024 -- For children with eosinophilic esophagitis, dupilumab results in a significantly higher percentage of histologic remission, according to a study...
FDA Approves Eohilia for Eosinophilic Esophagitis
FRIDAY, Feb. 16, 2024 -- The U.S. Food and Drug Administration has approved Eohilia (budesonide oral suspension) as the first and only oral treatment for eosinophilic esophagitis...
FDA Approves Dupilumab for Children With Eosinophilic Esophagitis
MONDAY, Jan. 29, 2024 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of pediatric patients (aged 1 to 11 years) with eosinophilic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.